These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19533640)

  • 21. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
    Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G
    J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Severe form of juvenile type II glycogenosis in a compound-heterozygous boy (Tyr-292--> Cys/Arg-854-->Stop)].
    Castro-Gago M; Eirís-Puñal J; Rodríguez-Núñez A; Pintos-Martínez E; Benlloch-Marín T; Barros-Angueira F
    Rev Neurol; 1999 Jul 1-15; 29(1):46-9. PubMed ID: 10528311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscle MRI findings in siblings with juvenile-onset acid maltase deficiency (Pompe disease).
    Dlamini N; Jan W; Norwood F; Sheehan J; Spahr R; Al-Sarraj S; Anthony Hulse J; Hughes D; Champion MP; Jungbluth H
    Neuromuscul Disord; 2008 May; 18(5):408-9. PubMed ID: 18434155
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA approves new treatment for late-onset Pompe disease.
    Home Healthc Nurse; 2010 Sep; 28(8):457. PubMed ID: 20811179
    [No Abstract]   [Full Text] [Related]  

  • 25. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
    Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
    Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Periodic acid-Schiff staining on resin muscle sections: improvement in the histological diagnosis of late-onset Pompe disease.
    Terracciano C; Rastelli E; Massa R
    Muscle Nerve; 2012 Apr; 45(4):611-2. PubMed ID: 22431097
    [No Abstract]   [Full Text] [Related]  

  • 27. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease.
    Yanovitch TL; Casey R; Banugaria SG; Kishnani PS
    J Neuroophthalmol; 2010 Jun; 30(2):165-6. PubMed ID: 20404746
    [No Abstract]   [Full Text] [Related]  

  • 28. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
    Goldstein JL; Young SP; Changela M; Dickerson GH; Zhang H; Dai J; Peterson D; Millington DS; Kishnani PS; Bali DS
    Muscle Nerve; 2009 Jul; 40(1):32-6. PubMed ID: 19533645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A retrospective study of six patients with late-onset Pompe disease].
    Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
    Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns.
    Carlier RY; Laforet P; Wary C; Mompoint D; Laloui K; Pellegrini N; Annane D; Carlier PG; Orlikowski D
    Neuromuscul Disord; 2011 Nov; 21(11):791-9. PubMed ID: 21803581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alpha-glucosidase (CHO) (Genzyme).
    Lachmann RH
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1101-10. PubMed ID: 15535432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Enzyme replacement therapy in Pompe's disease].
    Merk T; Wibmer T; Schumann C; Krüger S
    Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.
    Lollert A; Stihl C; Hötker AM; Mengel E; König J; Laudemann K; Gökce S; Düber C; Staatz G
    PLoS One; 2018; 13(1):e0190784. PubMed ID: 29315315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elimination of antibodies to recombinant enzyme in Pompe's disease.
    Mendelsohn NJ; Messinger YH; Rosenberg AS; Kishnani PS
    N Engl J Med; 2009 Jan; 360(2):194-5. PubMed ID: 19129538
    [No Abstract]   [Full Text] [Related]  

  • 36. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [26-year-old female patient with elevated liver enzymes].
    Martin K; Schlotter B; Müller-Höcker J; Loeschke K; Pongratz D; Folwaczny C
    Z Gastroenterol; 2002 Oct; 40(10):885-90. PubMed ID: 12436356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pompe's disease: the role for early diagnosis and treatment].
    Cerini E; Bini M; Donati A; Andaloro L; Compagnoni G
    Pediatr Med Chir; 2007; 29(5):270-2. PubMed ID: 18402397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
    Hunley TE; Corzo D; Dudek M; Kishnani P; Amalfitano A; Chen YT; Richards SM; Phillips JA; Fogo AB; Tiller GE
    Pediatrics; 2004 Oct; 114(4):e532-5. PubMed ID: 15466083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infantile and late onset form of generalised glycogenosis type II in cattle.
    Howell JM; Dorling PR; Cook RD; Robinson WF; Bradley S; Gawthorne JM
    J Pathol; 1981 Aug; 134(4):267-77. PubMed ID: 7033492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.